Reneuron Stem Cell Retinitis Pigmentosa

Thu 10 september 2020 16 00 a a a.

Reneuron stem cell retinitis pigmentosa.

We have worked with world leading collaborators and academic institutions in the retinal disease field to successfully take our retinitis pigmentosa programme through pre clinical development. About reneuron we are a leading clinical stage stem cell business. Our exosomes are derived from our ctx human neural stem cell line. Clinical development of hrpc for retinitis pigmentosa a blindness causing disease of the retina is progressing in the us and we have the.

Our hrpc stem cell therapy candidate for rp benefits from orphan drug designation in both europe and the us. Reneuron group plc aim. Cell based therapeutics developer reneuron group updated the market. Rp is a group of hereditary.

From our ctx human neural stem cell line. Retinitis pigmentosa is a group of hereditary diseases of the eye that lead to progressive loss of vision due to cells in the retina becoming damaged and eventually dying. Rene a global leader in the development of cell based therapeutics is pleased to announce positive long term data from the ongoing phase 1 2a clinical trial of its hrpc stem cell therapy candidate in retinitis pigmentosa rp and plans to expand the ongoing study. Reneuron upbeat on retinitis pigmentosa therapy development.